Name | Teicoplanin |
Synonyms | TEIC 8327A Tagocid MDL 507 Targocid Tecoplanine Tecoplanina Teicoplanin Teichomycin Tecoplaninum Teicoplanine Antibiotic 8327A Teicoplanin coMplex Teicoplanin sterile lyophilised teicoplanin Tecoplanine [INN-French] Tecoplaninum [INN-Latin] Tecoplanina [INN-Spanish] TEICOPLANIN [A(2-1) shown] TazobactuM SodiuM+Piperacillin SodiuM TeichoMycin, Tecoplanin, Targocid, TeicoMid, 8327A, DL 507IT, L 12507, MDL 507, MW 1900 |
CAS | 61036-62-2 |
EINECS | 1308068-626-2 |
InChI | InChI=1/C88H95Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h7-8,11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-6,9-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/b8-7+/t48?,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1 |
Molecular Formula | C78H77Cl2N8O32R |
Molar Mass | 1709.39 |
Density | 1.69g/cm3 |
Melting Point | 310 °C (decomp) |
Water Solubility | Sparingly soluble in water |
Solubility | H2O: soluble10mg/mL |
Appearance | powder |
Color | white to faint yellow |
Storage Condition | 2-8°C |
Refractive Index | 1.76 |
Physical and Chemical Properties | Soluble in methanol, ethanol, DMSO and other organic solvents. |
In vitro study | Teicoplanin is associated with a small increase in gastrointestinal colonization of Candida albicans. The inhibitory effect of Teicoplanin on proteoglycan polymerization rather than inhibition of nucleic acid and protein synthesis suggests that the effect of the wall is due to the accumulation of soluble precursors of proteoglycans continuously produced by cells at this level. Teicoplanin, at a concentration of 1 mg/ml, rapidly lysed the exponential phase cells of Streptococcus faecalis. In intact cells and cell-free systems, Teicoplanin inhibits peptidoglycan synthesis. Teicoplanin-induced lysis was dependent on the addition of antibiotics to the growth phase of B. pumilus. The cleavage of Strep. jhecalis CCM 1875 a longer lag phase induced by Teicoplanin, and the cleavage was not very extensive. |
In vivo study | In neutropenic mice, Teicoplanin increased survival, whereas G-CSF treatment did not. When compared with groups II,III,IV, Teicoplanin combined with G-CSF improved survival. |
WGK Germany | 3 |
RTECS | WY1559000 |
Reference Show more | 1. [IF=3.935] Rongying Luo et al."Preparation and application of teicoplanin functionalized polymeric monolith for enantioseparation of chiral drugs."J Pharmaceut Biomed. 2020 Apr;182:113129 |
Overview | Teicoplanin is a glycopeptide antibiotic produced by fermentation of the genus Actinomyces, it is a new generation of glycopeptide antibiotics developed after vancomycin, and is one of the most promising anti-drug resistant antibiotics in clinical practice in China. Compared with vancomycin, it has stronger fat solubility and longer half-life, it has good body fluid distribution, light adverse drug reactions, can be administered intravenously or intramuscularly, and is more convenient to use. |
preparation | A preparation method of teicoplanin, the preparation method is: teicoplanin was prepared by fermentation with teicoplanin-producing bacteria, and the teicoplanin was continuously removed from the fermentation system during the fermentation process, so that the content of teicoplanin in the fermentation system was less than 15 mg/L. |
pharmacology and toxicology | teicoplanin is a glycopeptide bactericidal antibiotic produced by the fermentation of Actinomycetes. The mechanism of action is to inhibit the synthesis of cell wall and interfere with the synthesis process of a new part of peptidoglycan. The drug binds to the bacterial cell wall mucopeptide during the period of division and reproduction, the amino acyl-D-alanyl-D-alanine at the end of the binding point of the mucopeptide, thereby preventing the synthesis of the bacterial cell wall membrane, to inhibit and kill bacteria. This product is effective against gram-positive aerobic and anaerobic bacteria, including Staphylococcus aureus and coagulase-negative staphylococcus (including methicillin-resistant strains), Streptococcus pyogenes, Pneumonia Streptococcus, Corynebacterium, Clostridium difficile, digestive Streptococcus, etc. This product is invalid for Gram-negative bacteria. |
indications | Clinical mainly for penicillin-resistant, cephalosporin Gram-positive bacterial infections, such as endocarditis, osteomyelitis, sepsis and respiratory tract, urinary tract, skin infections. |
biological activity | Teicoplanin (Teichomycin) is a prophylactic antibiotic. |